Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Facing progressive localized prostatic cancer

D W Newling1

  • 1Department of Urology, Academic Hospital, Free University, Amsterdam, The Netherlands.

European Urology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardization in pathologic assessment of transitional cell cancer of the bladder.

Urologic oncology·2011
Same author

The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables.

BJU international·2004
Same author

Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.

Journal of clinical pathology·2002
Same author

Laser therapy for carcinoma in situ of the penis.

The Journal of urology·2001
Same author

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

Urology·2001
Same author

Early versus late androgen deprivation therapy in metastatic disease.

Urology·2001
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
Same journal

Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.

European urology·2026
Same journal

Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026
Same journal

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
See all related articles

This review covers treatment options for locally progressive prostate cancer in three patient groups. It discusses therapeutic factors, effectiveness, and complications for advanced prostate cancer management.

Area of Science:

  • Oncology
  • Urology

Background:

  • Locally progressive prostate cancer presents unique challenges.
  • Patients fall into distinct groups based on disease stage and treatment history.

Purpose of the Study:

  • To review current treatment options for locally progressive prostate cancer.
  • To discuss factors influencing treatment decisions.
  • To present treatment effectiveness and associated complications.

Main Methods:

  • Literature review of available therapies for prostate cancer progression.
  • Analysis of factors guiding treatment selection.
  • Evaluation of treatment outcomes and side effects.

Main Results:

  • Identified three distinct patient cohorts with locally progressive prostate cancer.

Related Experiment Videos

  • Detailed review of therapeutic strategies for each group.
  • Summarized efficacy and complication profiles for various treatments.

    • Conclusions:

    • Optimal treatment for locally progressive prostate cancer depends on individual patient factors and disease characteristics.
    • A comprehensive understanding of treatment options, effectiveness, and complications is crucial for patient management.